Visual Performance of Clareon Vivity and PureSee IOL

About this trial

Last updated 9 months ago

Study ID

VOR2025-HGC-01

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

Accepting

50+ Years

All Sexes

Trial Timing

Ended 3 months ago

What is this trial about?

This is study to determine the visual performance of patients with age-related cataracts implanted in both eyes with either of two extended depth of focus intraocular lenses, the Clareon Vivity (Alcon Healthcare) or the PureSee (Johnson \& Johnson)

What are the participation requirements?

Inclusion Criteria

* Patients of any sex and race aged 50 years or older

* Patients undergoing bilateral age-related cataract surgery with a lens opacity grade 3 or higher in the LOCS III grading scale

* Willing to receive implantation of an EDOF IOL

* Willing to sign the informed consent and attend the study visits

Exclusion Criteria

* Requirement of a spherical or toric power of the IOL to achieve emmetropia beyond the available range of either of the two lenses

* The number of patients included with low astigmatism that require an equivalent to a T2 toric IOL will be capped to 10 patients/group

* Irregular astigmatism

* Contact lens wear in the previous 3 weeks before biometry

* Moderate or severe ocular surface, corneal, macular or optic nerve disease that in opinion of the investigator precludes the desired functional results

* History of previous refractive, cornea, retina or glaucoma surgery

* Eyes with a clear lens demanding a refractive lens exchange

* Amblyopia in any eye

* Significant previous ocular trauma

* Pregnancy

* A systemic condition that, in the opinion of the investigator, precludes the reliable assessments required in the study (i.e., dementia) or participation in the study (i.e., severe mobility problems).